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ABSTRACT 
Bietti’s crystalline dystrophy (BCD) is a rare disease presenting with the appearance of intraretinal crystalline deposits 
and varying degrees of chorioretinal atrophy commencing at the posterior pole. Within time, intraretinal crystals 
gradually disappear and chorioretinal atrophy extends beyond the macula even resulting in complete chorioretinal 
atrophy. Concomitant corneal crystals can be noted in 1/2 - 1/3 of the patients, and the presence of corneal crystals is 
not a must for establishing the diagnosis. For the past decade, genetic evaluations and newer imaging modalities expand 
our knowledge about the disease. CYP4V2 gene is found to be the gene responsible for the disease process and new 
mutations are still being described. Modern imaging modalities, such as a spectral domain optical coherence tomography 
(SD-OCT) shed light on the anatomic features of the disease. By this, we reiterate the rare and unusual clinical features of 
BCD. 
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INTRODUCTION 
In 1937, Bietti (1) described three cases of glistening, 
yellow- white intraretinal crystals in the posterior pole, 
atrophy of the retinal pigment epithelium (RPE), choroid 
sclerosis, crystals in the superficial paralimbal cornea 
with onset in the third decade of life. The condition was 
named after him, and subsequently, more cases with 
“Bietti’s crystalline dystrophy” (BCD) have been reported 
in the majority of ethnic groups. Its prevalence is 3% for 
all retinitis pigmentosa (RP) patients and 10% for 
autosomal recessive RP patients (2). Bietti crystalline 
dystrophy is, by all odds, related to aberrant oxidation of 
cellular lipid metabolism (3), caused by mutations of 
p450 genes (4). The disease is thought to be inherited in 
an autosomal recessive manner, and familial cases have 
also been documented (5, 6). Genetic mutations of the 
CYP4V2 gene are detected in >93.4% of cases by 
sequence analysis (7) and thus far, more than 50 
mutations have been described (8). Lai et al. (9) 
evaluated the genotype - phenotype analysis in BCD in a 
group of 18 Chinese patients in 13 families and showed 
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that BCD with homozygous IVS6-8del17 bp/insGC or 
compound heterozygous IVS6-8del17 bp/insGC and IVS8-
2A_G mutations appeared to have a more severe disease 
phenotype based on electrophysiological testing. In 
contrast, Rossi et al (10) described the clinical and 
genetic features of 15 Italian patients with BCD and 
illustrated that there was a large range of genotypic and 
phenotypic variations stressing out the lack of an explicit 
genotype-phenotype correlation. Wilson and colleagues 
(11) found crystals resembling cholesterol or cholesterol 
esters in the retina and complex lipid inclusions in the 
conjunctiva, cornea, fibroblasts and circulating 
lymphocytes. Lipid inclusions were also demonstrated in 
the choroid (12). 
 
CLINICAL FEATURES 
Clinical findings are mainly characterized by fundus 
changes described below and the presence of crystalline 
corneal deposits. 
Fundus Findings 
Clinical findings are mainly characterized by fundus 
Stamp of the disease is the presence of refractive 
polygonal, yellowish-white intraretinal crystals grouped 
around the posterior pole and at the transition zone 
between the normal and atrophic RPE (13-15). During 
the disease, crystals diminish in number and atrophy of 
the RPE and choriocapillaris begin to initially appear at 
the central fundus. With the time, chorioretinal atrophy 
expands centrifugally spreading to the retinal periphery 
as well. For that reason, patients between the second 
and fourth decade of life experience vision impairment, 
some degree of night blindness and visual field defects. 
However, age of onset, presenting symptoms and 
disease severity vary widely from case to case, and there 
can also be asymmetry between the eyes. Deterioration 
of vision can become so severe that the patient may 
even end up in legal blindness by the fifth or sixth decade 
of life. Patients can be staged into three groups -- early, 
intermediate and advanced disease, according to the 
clinical evaluation as suggested by Yuzawa et al. (16) and 
used later by Mataftsi et al. (2) and Fang et al. (15) with 
some minor modifications. 
Early disease: Crystals are scattered throughout the 
posterior pole and mid periphery. On fluorescein and 
indocyanine angiographies atrophy is limited to the 
posterior pole solely (Fig. 1a, b and c). 
Intermediate disease: Crystals are very few or absent at 
the posterior pole, but still visible outside the area of 
central atrophy extending up to the equator (Fig. 2a and 
b). 
Advanced disease: There is almost complete chorioretinal 
atrophy with very occasional crystals (Fig. 3a and b). 
 
Figure 1. Early disease, color fundus (1a), fluorescein angiographic (1b) and indocyanine green angiographic appearance (1c) 
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Figure 2. Intermediate disease, color fundus (2a), auto-fluorescence image (2b) and infrared image (2c) 
 
 
Figure 3. Advanced disease, color fundus (3a) and auto-fluorescence image (3b) 
 
Besides the ancillary tests such as fluorescein and 
indocyanine angiographies, newer imaging modalities 
such as spectral domain optical coherence tomography 
(SD-OCT) and auto-fluorescence imaging reveals 
additional morphological features of the disease process 
such as outer retinal tubulations (ORT) and hyper-
reflective dot-like lesions localized in almost all retinal 
layers (8, 17-22) (Figure 4-6). Outer retinal tubulations 
are more frequently described in BCD when compared 
with other retinal dystrophies such as RP and cone 
dystrophy (20, 21).  
Only in Yin’s et al. study comprising 17 patients, ORT was 
present in just 13.6% of eyes with BCD (23).Countless 
bright reflective spots of various configurations such as 
highly reflective spots in the inner retina, bright 
reflective plaques on top of Bruch membrane or partially 
encapsulated reflective plaques are all shown in SD-OCT 
sections of patients with BCD (19). However, only some 
of the hyper-reflective dots seem to correspond to the 
crystalline deposits (17, 19). The rest of the hyper-
reflective dots may also be related to the inflammatory 
cells, protein deposits, a glial response to retinal 
degeneration, or even be artefacts (8). 
Toto et al. (22) argued that choroidal hyper-reflective 
dots were in fact crystals resided in the choroid, thus 
they just added to the controversy of presence of hyper-
reflective dots in the choroid. 
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Figure 4. Outer retinal tubulations (yellow arrow), Bright plaque (red arrow) 
 
 
 
Figure 5. Outer retinal tubulations (yellow arrow), Bright plaque (red arrow), Intraretinal bright spots (blue arrow), Choroidal bright spots (green 
arrow) 
 
 
Figure 6. Outer retinal tubulations (yellow arrow), Bright plaque (red arrow), Intraretinal bright spots (blue arrow) 
 
Auto-fluorescence imaging shows decreased auto-
fluorescence corresponding to the areas of RPE loss; 
punctual increase of auto-fluorescence corresponds to 
pigment dots, possible RPE hyperplasia or limited 
hyperauto-fluorescence of the crystals (17). 
Trailing the evolving disease, macular function 
deteriorates as well. Some very rarely encountered 
macular changes may further affect the visual acuity 
devastatingly. Subfoveal neurosensory detachment (24), 
subretinal neovascular membrane (25-28), macular hole 
(29, 30) and cystoid macular edema (31, 32) are among 
those. 
As the diagnosis mainly relies upon clinical features, 
electrophysiological tests are not as mandatory as in 
other retinal dystrophies. However, electrophysiological 
tests can be helpful to show the extent of the damage. 
The full field ERG can show extent of rod and cone 
dysfunction ranging from normal to reduced amplitudes 
of scotopic and photopic response to undetectable 
stimuli (33). On the other hand, multifocal ERG may 
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detect regional areas of abnormal function wherever the 
full field ERG is normal (34). 
Differential diagnosis of intraretinal crystalline deposits 
includes primary hyperoxaluria type 1 and 2, cystinosis, 
Sjögren-Larsson syndrome, drug-toxicity (tamoxifen, 
methoxyflurane and canthaxanthin) and talc retinopathy 
(7). 
 
CORNEAL FEATURES 
Corneal crystals (figure 7) are very fine and located 
mainly in the subepithelial and superficial anterior 
stroma near the limbus. In 1/3 - 1/2 of cases can be 
observed at the slit-lamp examination (12). However, 
corneal crystals can easily be overlooked, even by an 
experienced ophthalmologists as these deposits are very 
subtle (35). Specular microscopy (36) and in vivo 
confocal microscopy (37) were used to detect the 
corneal crystalline deposits very recently. 
 
 
Figure 7. Limbal Crystals 
 
CONCLUSION 
The diagnosis of BCD is made by the typical clinical 
findings of discrete glistening crystals within the retina. 
After excluding other causes of crystalline retinopathy 
with the help of clinical history and systemic evaluation 
diagnosis is confirmed by finding of the mutations in 
CYP4V2 gene. New imaging modalities such as SD-OCT 
provide novel information about the anatomic location 
and clinical implications of retinal crystals. 
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